|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study显示文摘Background:Famitinib is a tyrosine kinase inhibitor against multiple targets,including vascular endothelial growth factor receptor 2/3,platelet-derived growth factor receptor,and stem cell factor receptor(c-kit).Previous studies have demonstrated anti-tumour activities of famitinib against a wide variety of advanced-stage solid cancers.We aimed to determine the safety and efficacy of famitinib with concurrent chemoradiotherapy(CCRT)in patients with locoregionally advanced nasopharyngeal carcinoma(NPC).We also evaluated the feasibility of contrast-enhanced ultrasound(D-CEUS)as a predictor of early tumour response to famitinib and to correlate functional parameters with clinical efficacy.Methods:The trial was conducted in subjects with stage III or IVa-b NPC using a 3+3 design of escalating fami-tinib doses.Briefly,subjects received 2 weeks of famitinib monotherapy followed by 7 weeks of famitinib plus CCRT.D-CEUS of the neck lymph nodes was performed at day 0,8 and 15 after famitinib was administered before starting concurrent chemoradiotherapy.End points included safety,tolerability and anti-tumour activity.Results:Twenty patients were enrolled(six each for 12.5,16.5 and 20 mg and two for 25 mg).Two patients in the 25 mg cohort developed dose-limiting toxicities,including grade 4 thrombocytopenia and grade 3 hypertension.The most common grade 3/4 adverse events were leukopenia,neutropenia and radiation mucositis.D-CEUS tests showed that more than 60%of patients achieved a perfusion parameter response after 2 weeks taking famitinib alone,and the parameter response was associated with disease improvement.In the famitinib monotherapy stage,three patients(15%)showed partial responses.The complete response rate was 65%at the completion of treatment and 95%3 months after the treatment ended.After a median follow-up of 44 months,the 3-year progression-free survival(PFS)and distant metastasis-free survival were 70%and 75%,respectively.Subjects with a decrease of perfusion parameter response,such as peak intensity decreased at least 30%after 1 week of famitinib treatment,had higher 3-year PFS(90.9%vs.44.4%,95%CI 73.7%-100%vs.11.9%-76.9%,P<0.001)than those with an increase or a reduction of less than 30%.Conclusions:The recommended famitinib dose for phase II trial is 20 mg with CCRT for patients with local advanced NPC.D-CEUS is a reliable and early measure of efficacy for famitinib therapies.Further investigation is required to confirm the effects of famitinib plus chemoradiotherapy. | Qiuyan Chen Linquan Tang Na Liu Feng Han Ling Guo Shanshan Guo Jianwei Wang Huai Liu Yanfang Ye Lu Zhang Liting Liu Pan Wang Yingqin Li Qingmei He Xiaoqun Yang Qingnan Tang Yang Li YuJing Liang XueSong Sun Chuanmiao Xie Yunxian Mo Ying Guo Rui Sun Haoyuan Mo Kajia Cao Xiang Guo Musheng Zeng Haiqiang Mai Jun Ma | 2018 | Cancer Communications2018，38，1： | 6 |
| 2 | Star-shaped polymers consisting of a β-cyclodextrin core and poly(amidoamine) dendron arms: binding and release studies with methotrexate and siRNA显示文摘 | Deng JunJie Li Na Mai KaiJin | 2011 | J Mater Chem2011，，21： | 1 |
| 3 | A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia显示文摘 | EVINS AE MAYS VK RIGOYYI NA etal | 2001 | Nicotine Tob Res2001，3，4： | 1 |
| 4 | Biosorption of chromium from aqueous solution and electroplating wastewater using mixture of Candida lipolytica and dewatered sewage sludge显示文摘 | YE Jin-shao YIN Hua MAI Bi-xian PENG Hui QIN Hua-ming HE Bao-yan ZHANG Na | | 0，，11： | 1 |
| 5 | Star-shaped polymers consisting of a β-eyclodextrin core and poly ( anaidoamine ) denron arms:binding and release studies with methotrexate and siRNA显示文摘 | DENG Junjie LI Na MAI Kaijin | 2011 | J Mater Chem2011，，21： | 1 |
| 6 | Androgen receptor coregulator ARA267-α interacts with death receptor-6 revealed by the yeast two-hybrid显示文摘ARA267-a is a newly identified androgen receptor coactivator. In order to further elucidate its precise role in cells, using the ARA267- a fragment containing four PHD and one SET conserved domains as bait we revealed an ARA267-a-PHD-SET-interacting protein, death receptor-6 (DR6), in the yeast two-hybrid screening. DR6 is the member of TNF receptor family and has a death domain in its intracellular cytoplasmic portion (DR6cp) to mediate the cell apoptosis. The interaction between ARA267-a-PHD-SET and DR6cp was confirmed in vitro and in vivo. Our finding implied that androgen signaling pathway might cross talk with apoptosis sig-naling pathway through the interaction between ARA267-a and DR6. | MAI Tiejun1*, WANG Xin2*, ZHANG Zhiwen3, XIN Dianqi1, NA Yanqun1 & GUO Yinglu1 1. Institute of Urology, First Hospital of Peking University, Beijing 100034, China 2. Department of General Surgery, First Hospital of Peking University, Beijing 100034, China 3. Department of Physiology, Peking University, Beijing 100083, China | 2004 | Science China(Life Sciences)2004，47，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员